Literature DB >> 3129507

Recombinant granulocyte-macrophage colony-stimulating factor down-regulates expression of IL-2 receptor on human mononuclear phagocytes by induction of prostaglandin E.

W W Hancock1, M E Pleau, L Kobzik.   

Abstract

Recent studies have shown that normal human alveolar macrophages and blood monocytes, as well as HL-60 and U937 monocyte cell lines, newly express IL-2R after stimulation with rIFN-gamma or LPS. In addition, macrophages transiently express IL-2R in vivo during immunologically mediated diseases such as pulmonary sarcoidosis and allograft rejection. We therefore investigated in vitro factors that modulate macrophage expression of IL-2R. IL-2R were induced on normal alveolar macrophages, blood monocytes, and HL-60 cells using rIFN-gamma (24 to 48 h at 240 U/ml), and cells were cultured for an additional 12 to 24 h with rIL-2 (100 U/ml), recombinant granulocyte-macrophage CSF (rGM-CSF, 1000 U/ml), rGM-CSF plus indomethacin (2 X 10(-6) M), PGE2 (0.1 to 10 ng/ml), 1 X 10(-6) M levels of caffeine, theophylline, and dibutyryl cyclic AMP, or medium alone. IL-2R expression was quantitated by cell ELISA (HL-60 cells) or determined by immunoperoxidase staining (alveolar macrophages, blood monocytes, and HL-60 cells), using anti-Tac and other CD25 mAb. PGE production was assayed by RIA. We found greater than 95% of alveolar macrophages, monocytes, and HL-60 cells expressed IL-2R after rIFN-gamma treatment and remained IL-2R+ in the presence of IL-2R or medium alone. By comparison, greater than 95% of cells induced to express IL-2R became IL-2R- after addition of rGM-CSF, and the culture supernatants from GM-CSF-treated cells contained increased levels of PGE. This inhibition of macrophage IL-2R expression by rGM-CSF was blocked by indomethacin, and IL-2R+ macrophages became IL-2R- after addition of PGE2 alone. These findings indicate GM-CSF down-regulates IL-2R expression by human macrophages via induction of PGE synthesis. Moreover, a similar down-regulation of IL-2R expression was seen after stimulation with caffeine, theophylline, or dibutyryl cyclic AMP. Hence, GM-CSF, PGE, and other pharmacologic agents that act to increase intracellular levels of cAMP may play a modulatory role, antagonistic to that of IFN-gamma on cellular expression of IL-2R by human inflammatory macrophages in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129507

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Modulation of myelopoiesis by prostaglandin E2: demonstration of a novel mechanism of action in vivo.

Authors:  L M Pelus
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

2.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

3.  Modulation of in vitro antitumor immunity in response to the biological activators interleukin-2, gamma interferon, and granulocyte monocyte-colony stimulating factor in the peripheral blood of cancer patients receiving cytotoxic chemotherapy.

Authors:  J E Harris; D P Braun
Journal:  Bull N Y Acad Med       Date:  1989-01

4.  In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes.

Authors:  Y Sawamura; A C Diserens; N de Tribolet
Journal:  J Neurooncol       Date:  1990-10       Impact factor: 4.130

5.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) has opposing effects on the capacity of monocytes versus monocyte-derived dendritic cells to stimulate the antigen-specific proliferation of a human T cell clone.

Authors:  H C Heystek; G C Mudde; R Ohler; F S Kalthoff
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

6.  The in vitro development of cytotoxicity in response to granulocyte/macrophage-colony-stimulating factor or interferon gamma in the peripheral blood monocytes of patients with solid tumors: modulation by arachidonic acid metabolic inhibitors.

Authors:  D P Braun; K P Siziopikou; L C Casey; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  The tumor necrosis factor receptor and human neutrophil function. Deactivation and cross-deactivation of tumor necrosis factor-induced neutrophil responses by receptor down-regulation.

Authors:  B Schleiffenbaum; J Fehr
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

8.  Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.

Authors:  G Masucci; P Wersäll; P Ragnhammar; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

9.  Production of granulocyte-macrophage colony-stimulating factor by cultured human tracheal epithelial cells.

Authors:  L Churchill; B Friedman; R P Schleimer; D Proud
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

10.  Granulocyte-macrophage colony-stimulating factor increases the infectivity of Leishmania amazonensis by protecting promastigotes from heat-induced death.

Authors:  M A Barcinski; D Schechtman; L G Quintao; D de A Costa; L R Soares; M E Moreira; R Charlab
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.